An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) will participate in a webinar titled Unlocking the Value of Digital Prescription Therapeutics on June 16, 2022, at 10:00 a.m. ET. The event, hosted by Cowen, will discuss promising results from the pivotal clinical trial of BT-001, a digital therapeutic for type 2 diabetes that significantly outperformed traditional pharmaceutical treatments in reducing A1c levels. Key speakers include Mark Berman, Prapti Mehta, and Marc Bonaca, who will elaborate on the implications of these findings for current diabetes treatment.
Positive
None.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss the recently released promising pivotal clinical trial data for BT-001, its digital therapeutic platform for type 2 diabetes, and how BT-001 may be used in the current type 2 diabetes treatment paradigm.
WHEN:Thursday, June 16, 2022 at 10:00 a.m. ET
WHAT: The Unlocking the Value of Digital Prescription Therapeutics webinar will be hosted by Charles Rhyee, an equity research analyst with Cowen, and will provide an opportunity to review the primary endpoint results from the company’s pivotal clinical trial for BT-001 and discuss how BT-001 may be used in the current type 2 diabetes treatment paradigm. Released earlier this year, the pivotal clinical trial demonstrated significant reduction in A1c levels that surpassed results seen in patients using pharmaceutical solutions alone.
WHO:
Mark Berman, MD, Chief Medical Officer, Better Therapeutics
Marc Bonaca, MD, MPH, Director of Vascular Research at Colorado Prevention Center, Professor of Medicine at University of Colorado School of Medicine
WHERE: Cowen hosted events are intended for prospective and existing Cowen clients only. To listen to the live event, please contact your Cowen representative.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
